Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.51 |
| ▸ | POLA1 | P09884 | 2/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.43 |
| ▸ | MERTK | Q12866 | 1/20 | 0.43 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6699267 | 0.85 | MAPK1 (0.42) | RXFP1ALDH1A1TSHR | |
| SCHEMBL6202555 | 0.82 | RXFP1 (0.49) | KCNH2POLA1RXFP1ALDH1A1 | |
| SCHEMBL6201283 | 0.81 | KCNH2 (0.54) | KCNH2POLA1RXFP1ALDH1A1 | |
| SCHEMBL6200655 | 0.81 | KCNH2 (0.48) | KCNH2POLA1RXFP1ALDH1A1 | |
| SCHEMBL6606941 | 0.80 | POLA1 (0.53) | KCNH2POLA1RXFP1ALDH1A1TSHR | |
| SCHEMBL6200011 | 0.80 | KCNH2 (0.53) | KCNH2POLA1RXFP1ALDH1A1 | |
| SCHEMBL6726994 | 0.80 | KCNH2 (0.55) | KCNH2POLA1RXFP1ALDH1A1TSHR | |
| SCHEMBL6770778 | 0.80 | KCNH2 (0.53) | KCNH2POLA1RXFP1ALDH1A1TSHR | |
| SCHEMBL6707995 | 0.80 | KCNH2 (0.61) | KCNH2POLA1RXFP1ALDH1A1TSHR | |
| SCHEMBL6669690 | 0.80 | KCNH2 (0.50) | KCNH2POLA1RXFP1ALDH1A1FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040067947-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-04-08 | — | — | US | claimed |
| EP-1265896-A1 | 4-HYDROXY-1,8-NAPHTHYRIDINE-3-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-18 | — | — | EP | claimed |
| US-6413958-B2 | FOR TREATMENT/PREVENTION OF INFECTION OF HERPES SIMPLEX VIRUS, VARICELLA ZOSTER VIRUS, HUMAN CYTOMEGALOVIRUS, OR EPSTEIN-BARR VIRUS; ENZYME INHIBITORS | PHARMACIA & UPJOHN COMPANY | 2002-07-02 | — | — | US | claimed |
| US-20020007066-A1 | 4-hydroxy-1,8-naphthyridine-3-carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-01-17 | — | — | US | claimed |
| WO-2001070742-A1 | 4-HYDROXY-1,8-NAPHTHYRIDINE-3-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-09-27 | — | — | WO | claimed |
| US-20040067947-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-04-08 | — | — | US | disclosed |
| EP-1265896-A1 | 4-HYDROXY-1,8-NAPHTHYRIDINE-3-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| US-6413958-B2 | FOR TREATMENT/PREVENTION OF INFECTION OF HERPES SIMPLEX VIRUS, VARICELLA ZOSTER VIRUS, HUMAN CYTOMEGALOVIRUS, OR EPSTEIN-BARR VIRUS; ENZYME INHIBITORS | PHARMACIA & UPJOHN COMPANY | 2002-07-02 | — | — | US | disclosed |
| US-20020007066-A1 | 4-hydroxy-1,8-naphthyridine-3-carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-01-17 | — | — | US | disclosed |
| WO-2001070742-A1 | 4-HYDROXY-1,8-NAPHTHYRIDINE-3-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020007066-A1 | 4-hydroxy-1,8-naphthyridine-3-carboxamides as antiviral agents | CNR1, HAVCR2, NR1H4 | KCNH2 2146/4885POLA1 849/4885RXFP1 2426/4885 |
| US-20040067947-A1 | Method of preventing or treating atherosclerosis or restenosis | LDLR, MSR1, NR1H2 | KCNH2 4046/4885POLA1 2850/4885RXFP1 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.